JP2018519328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519328A5 JP2018519328A5 JP2017568203A JP2017568203A JP2018519328A5 JP 2018519328 A5 JP2018519328 A5 JP 2018519328A5 JP 2017568203 A JP2017568203 A JP 2017568203A JP 2017568203 A JP2017568203 A JP 2017568203A JP 2018519328 A5 JP2018519328 A5 JP 2018519328A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- disorders
- compound according
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 99
- 150000003839 salts Chemical class 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000014617 hemorrhoid Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 229930182558 Sterol Natural products 0.000 claims description 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 235000003702 sterols Nutrition 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- 206010011878 Deafness Diseases 0.000 claims description 3
- 230000010370 hearing loss Effects 0.000 claims description 3
- 231100000888 hearing loss Toxicity 0.000 claims description 3
- 208000016354 hearing loss disease Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002091 Anaesthesia Diseases 0.000 claims description 2
- 206010048946 Anal abscess Diseases 0.000 claims description 2
- 208000016583 Anus disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 206010039897 Sedation Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010042458 Suicidal ideation Diseases 0.000 claims description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 230000006978 adaptation Effects 0.000 claims description 2
- 230000037005 anaesthesia Effects 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 208000018459 dissociative disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 230000001037 epileptic effect Effects 0.000 claims description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 208000014081 polyp of colon Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 208000022610 schizoaffective disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000036280 sedation Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 125000002328 sterol group Chemical group 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 8
- 0 C[C@](CCC(*)O)[C@@](CC1)[C@@](C)(CC2)[C@]1C(CC1)[C@]2[C@@](C)(CC2)C1=C[C@@]2(*)O Chemical compound C[C@](CCC(*)O)[C@@](CC1)[C@@](C)(CC2)[C@]1C(CC1)[C@]2[C@@](C)(CC2)C1=C[C@@]2(*)O 0.000 description 3
- 230000002265 prevention Effects 0.000 description 2
- INTUGXQTDFSWLD-LMDOIDTISA-N CC(C)[C@@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O Chemical compound CC(C)[C@@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O)O INTUGXQTDFSWLD-LMDOIDTISA-N 0.000 description 1
- DEERKMBWSUJANS-MXOMLNPXSA-N CCC(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](CC)(C2)O)C2=CC1)O Chemical compound CCC(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](CC)(C2)O)C2=CC1)O DEERKMBWSUJANS-MXOMLNPXSA-N 0.000 description 1
- DEERKMBWSUJANS-IAGOMVBCSA-N CC[C@@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](CC)(C2)O)C2=CC1)O Chemical compound CC[C@@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](CC)(C2)O)C2=CC1)O DEERKMBWSUJANS-IAGOMVBCSA-N 0.000 description 1
- DEERKMBWSUJANS-RJYNCZEQSA-N CC[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](CC)(C2)O)C2=CC1)O Chemical compound CC[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](CC)(C2)O)C2=CC1)O DEERKMBWSUJANS-RJYNCZEQSA-N 0.000 description 1
- MQCWPYXLTZVFRH-WJNVTGPNSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@H](C(C)C)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@H](C(C)C)O)O MQCWPYXLTZVFRH-WJNVTGPNSA-N 0.000 description 1
- QRVQZZZXIGSOMU-DGLGDPJDSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)C3[C@H](C)CCC(C3CC3)O)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)C3[C@H](C)CCC(C3CC3)O)[C@H]4[C@@]2(C)CC1)O QRVQZZZXIGSOMU-DGLGDPJDSA-N 0.000 description 1
- LZSGVZPIZJGXBD-BISNXJFYSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CCC(C)O)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CCC(C)O)[C@H]4[C@@]2(C)CC1)O LZSGVZPIZJGXBD-BISNXJFYSA-N 0.000 description 1
- IYUIIRFZGXKEKL-BBTOXVIXSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CCCO)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CCCO)[C@H]4[C@@]2(C)CC1)O IYUIIRFZGXKEKL-BBTOXVIXSA-N 0.000 description 1
- LZSGVZPIZJGXBD-UPSGSUDHSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CC[C@@H](C)O)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CC[C@@H](C)O)[C@H]4[C@@]2(C)CC1)O LZSGVZPIZJGXBD-UPSGSUDHSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189068P | 2015-07-06 | 2015-07-06 | |
| US62/189,068 | 2015-07-06 | ||
| US201662332931P | 2016-05-06 | 2016-05-06 | |
| US62/332,931 | 2016-05-06 | ||
| PCT/US2016/041175 WO2017007840A1 (en) | 2015-07-06 | 2016-07-06 | Oxysterols and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020215040A Division JP2021046444A (ja) | 2015-07-06 | 2020-12-24 | オキシステロールおよびそれらの使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018519328A JP2018519328A (ja) | 2018-07-19 |
| JP2018519328A5 true JP2018519328A5 (enExample) | 2019-07-25 |
Family
ID=57686127
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568203A Withdrawn JP2018519328A (ja) | 2015-07-06 | 2016-07-06 | オキシステロールおよびそれらの使用の方法 |
| JP2020215040A Withdrawn JP2021046444A (ja) | 2015-07-06 | 2020-12-24 | オキシステロールおよびそれらの使用の方法 |
| JP2022091046A Active JP7602512B2 (ja) | 2015-07-06 | 2022-06-03 | オキシステロールおよびそれらの使用の方法 |
| JP2024213248A Pending JP2025026574A (ja) | 2015-07-06 | 2024-12-06 | オキシステロールおよびそれらの使用の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020215040A Withdrawn JP2021046444A (ja) | 2015-07-06 | 2020-12-24 | オキシステロールおよびそれらの使用の方法 |
| JP2022091046A Active JP7602512B2 (ja) | 2015-07-06 | 2022-06-03 | オキシステロールおよびそれらの使用の方法 |
| JP2024213248A Pending JP2025026574A (ja) | 2015-07-06 | 2024-12-06 | オキシステロールおよびそれらの使用の方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11117924B2 (enExample) |
| EP (3) | EP3319612B1 (enExample) |
| JP (4) | JP2018519328A (enExample) |
| KR (2) | KR102993541B1 (enExample) |
| CN (3) | CN108135911B (enExample) |
| AU (4) | AU2016289971C1 (enExample) |
| CA (1) | CA2991313C (enExample) |
| CO (1) | CO2018000589A2 (enExample) |
| CY (1) | CY1124620T1 (enExample) |
| DK (2) | DK3812392T3 (enExample) |
| ES (2) | ES3036110T3 (enExample) |
| FI (1) | FI3812392T3 (enExample) |
| HR (2) | HRP20250799T1 (enExample) |
| HU (2) | HUE071964T2 (enExample) |
| IL (3) | IL289976B2 (enExample) |
| LT (2) | LT3812392T (enExample) |
| MA (1) | MA54851A (enExample) |
| MD (1) | MD3319612T2 (enExample) |
| MX (3) | MX2021005052A (enExample) |
| MY (1) | MY197698A (enExample) |
| PE (1) | PE20180482A1 (enExample) |
| PH (2) | PH12020551586A1 (enExample) |
| PL (2) | PL3812392T3 (enExample) |
| PT (2) | PT3812392T (enExample) |
| RS (2) | RS62220B1 (enExample) |
| RU (1) | RU2742333C2 (enExample) |
| SG (1) | SG10202002655VA (enExample) |
| SI (2) | SI3812392T1 (enExample) |
| SM (2) | SMT202100476T1 (enExample) |
| WO (1) | WO2017007840A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| WO2017007832A1 (en) * | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| DK3529257T3 (da) * | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN113121631B (zh) * | 2021-03-25 | 2023-02-03 | 西北农林科技大学 | 一种羊毛甾烷灵芝三萜类化合物、制备方法及应用 |
| EP4351588A1 (en) | 2021-06-11 | 2024-04-17 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2025020191A1 (zh) * | 2023-07-27 | 2025-01-30 | 珂阑(上海)医药科技有限公司 | 甾类化合物、其制备方法和应用 |
| CN121758535A (zh) * | 2025-12-15 | 2026-03-31 | 北京工商大学 | 一种胆固醇衍生物、其制备方法与应用 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS6253960A (ja) | 1985-05-30 | 1987-03-09 | Taisho Pharmaceut Co Ltd | ビタミンｄ↓３の誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DK1038880T3 (da) | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| BR9509764A (pt) | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| US6780853B1 (en) * | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| PT837874E (pt) | 1995-06-06 | 2005-03-31 | Euro Celtique Sa | Esteroides neuroactivos da serie androstano e pregnano |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| ATE254628T1 (de) | 1995-06-23 | 2003-12-15 | Novo Nordisk As | Meiose regulierende verbindungen. |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| CA2331299A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| US6376530B1 (en) * | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| JP4309661B2 (ja) | 2001-05-03 | 2009-08-05 | ザ ユニバーシティー オブ シカゴ | 肝臓ｘ受容体 |
| WO2003039480A2 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| PL213697B1 (pl) | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| GB0216621D0 (en) * | 2002-07-17 | 2002-08-28 | Imaging Res Solutions Ltd | Imaging compounds |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| US20060160853A1 (en) * | 2002-11-22 | 2006-07-20 | Mccauley John A | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| EP1814558B1 (en) | 2004-11-01 | 2010-12-15 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| AU2007217366A1 (en) | 2006-02-27 | 2007-08-30 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| EP2711372A1 (en) | 2006-11-21 | 2014-03-26 | Umecrine AB | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders |
| AU2008265595B2 (en) | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| US20110118353A1 (en) | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| WO2009094279A1 (en) | 2008-01-25 | 2009-07-30 | Merck & Co., Inc. | Quinolizidinone m1 receptor positive allosteric modulators |
| TWI478709B (zh) * | 2008-02-19 | 2015-04-01 | Earnest Medicine Co Ltd | A useful oral or enteral composition for the recovery of bodily functions |
| US8497122B2 (en) * | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
| WO2009137843A2 (en) | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| DK2444092T3 (en) * | 2008-05-28 | 2015-09-28 | Reveragen Biopharma Inc | Non-hormonal steroidmodulatorer of NF-? B for the treatment of disease |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| JP2013500986A (ja) | 2009-07-29 | 2013-01-10 | ザ・ユニバーシティ・オブ・シカゴ | 肝臓ｘ受容体アゴニスト |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| JP2011135864A (ja) * | 2009-12-30 | 2011-07-14 | Korea Univ Research & Business Foundation | Ｏｃｔ４及びＢｍｉ１、またはその上位調節子を用いて体細胞から胚幹細胞類似細胞への逆分化を誘導する組成物及びこれを用いた胚幹細胞類似細胞の製造方法 |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| GB201008047D0 (en) * | 2010-05-14 | 2010-06-30 | Ge Healthcare Ltd | Method of synthesis |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| AU2012262520A1 (en) | 2011-05-27 | 2014-01-23 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| HUE062616T2 (hu) * | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| US8648079B2 (en) | 2011-10-07 | 2014-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| US9737522B2 (en) | 2012-08-09 | 2017-08-22 | Emory University | NMDA receptor modulators and uses related thereto |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| CN104736176B (zh) * | 2012-08-24 | 2017-10-13 | 英特格拉斯疗法有限公司 | 用于增强治疗剂透皮递送的化学组合物和方法 |
| DK2935307T3 (en) | 2012-12-18 | 2018-07-30 | Univ Washington | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT |
| WO2014115167A2 (en) | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
| JP6419087B2 (ja) | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| CN112057457A (zh) * | 2013-03-13 | 2020-12-11 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| HK1222565A1 (zh) | 2013-09-25 | 2017-07-07 | 范安德尔研究所 | 高效糖皮質激素 |
| CN103655582B (zh) * | 2013-11-30 | 2015-05-27 | 浙江大学 | 一种环氧甾醇组合物及制备和用途 |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| EP3166613A4 (en) | 2014-07-09 | 2018-02-21 | Duke University | Compositions and methods for the repair of myelin |
| US10016095B2 (en) * | 2014-10-03 | 2018-07-10 | Progressive International Corporation | Salad spinner |
| BR112017007053A2 (pt) | 2014-10-07 | 2018-06-19 | Sage Therapeutics Inc | compostos neuroativos e métodos de utilização deste composto. |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| WO2017007832A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| DK3529257T3 (da) | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| IL271343B2 (en) | 2017-06-23 | 2023-12-01 | Intercept Pharmaceuticals Inc | Methods and intermediates for the preparation of bile acid derivatives |
| SG11202004329TA (en) | 2017-11-10 | 2020-06-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
-
2016
- 2016-07-06 DK DK20214736.9T patent/DK3812392T3/da active
- 2016-07-06 RS RS20211000A patent/RS62220B1/sr unknown
- 2016-07-06 MA MA054851A patent/MA54851A/fr unknown
- 2016-07-06 CN CN201680050744.1A patent/CN108135911B/zh active Active
- 2016-07-06 RS RS20250662A patent/RS66996B1/sr unknown
- 2016-07-06 CA CA2991313A patent/CA2991313C/en active Active
- 2016-07-06 MX MX2021005052A patent/MX2021005052A/es unknown
- 2016-07-06 SI SI201631911T patent/SI3812392T1/sl unknown
- 2016-07-06 FI FIEP20214736.9T patent/FI3812392T3/fi active
- 2016-07-06 EP EP16821926.9A patent/EP3319612B1/en active Active
- 2016-07-06 US US15/742,424 patent/US11117924B2/en active Active
- 2016-07-06 EP EP20214736.9A patent/EP3812392B1/en active Active
- 2016-07-06 RU RU2018104245A patent/RU2742333C2/ru active
- 2016-07-06 ES ES20214736T patent/ES3036110T3/es active Active
- 2016-07-06 MX MX2020010690A patent/MX390271B/es unknown
- 2016-07-06 AU AU2016289971A patent/AU2016289971C1/en active Active
- 2016-07-06 WO PCT/US2016/041175 patent/WO2017007840A1/en not_active Ceased
- 2016-07-06 PH PH1/2020/551586A patent/PH12020551586A1/en unknown
- 2016-07-06 SM SM20210476T patent/SMT202100476T1/it unknown
- 2016-07-06 PT PT202147369T patent/PT3812392T/pt unknown
- 2016-07-06 MX MX2018000280A patent/MX382122B/es unknown
- 2016-07-06 EP EP25170345.0A patent/EP4599887A3/en active Pending
- 2016-07-06 HU HUE20214736A patent/HUE071964T2/hu unknown
- 2016-07-06 HR HRP20250799TT patent/HRP20250799T1/hr unknown
- 2016-07-06 JP JP2017568203A patent/JP2018519328A/ja not_active Withdrawn
- 2016-07-06 IL IL289976A patent/IL289976B2/en unknown
- 2016-07-06 CN CN202411074416.8A patent/CN118994288A/zh active Pending
- 2016-07-06 MD MDE20180513T patent/MD3319612T2/ro unknown
- 2016-07-06 SG SG10202002655VA patent/SG10202002655VA/en unknown
- 2016-07-06 HR HRP20211282TT patent/HRP20211282T1/hr unknown
- 2016-07-06 SI SI201631298T patent/SI3319612T1/sl unknown
- 2016-07-06 PE PE2018000037A patent/PE20180482A1/es unknown
- 2016-07-06 PL PL20214736.9T patent/PL3812392T3/pl unknown
- 2016-07-06 KR KR1020247037600A patent/KR102993541B1/ko active Active
- 2016-07-06 PL PL16821926T patent/PL3319612T3/pl unknown
- 2016-07-06 SM SM20250264T patent/SMT202500264T1/it unknown
- 2016-07-06 IL IL282048A patent/IL282048B2/en unknown
- 2016-07-06 LT LTEP20214736.9T patent/LT3812392T/lt unknown
- 2016-07-06 LT LTEP16821926.9T patent/LT3319612T/lt unknown
- 2016-07-06 DK DK16821926.9T patent/DK3319612T3/da active
- 2016-07-06 PT PT168219269T patent/PT3319612T/pt unknown
- 2016-07-06 MY MYPI2018000010A patent/MY197698A/en unknown
- 2016-07-06 CN CN202110635348.8A patent/CN113501855A/zh active Pending
- 2016-07-06 KR KR1020187003209A patent/KR20180026742A/ko not_active Ceased
- 2016-07-06 ES ES16821926T patent/ES2884086T3/es active Active
- 2016-07-06 HU HUE16821926A patent/HUE055199T2/hu unknown
-
2017
- 2017-12-24 IL IL256531A patent/IL256531B/en active IP Right Grant
-
2018
- 2018-01-05 PH PH12018500061A patent/PH12018500061A1/en unknown
- 2018-01-22 CO CONC2018/0000589A patent/CO2018000589A2/es unknown
-
2020
- 2020-12-24 JP JP2020215040A patent/JP2021046444A/ja not_active Withdrawn
-
2021
- 2021-08-06 US US17/396,034 patent/US11732000B2/en active Active
- 2021-08-13 CY CY20211100733T patent/CY1124620T1/el unknown
- 2021-08-20 AU AU2021218230A patent/AU2021218230B2/en active Active
-
2022
- 2022-06-03 JP JP2022091046A patent/JP7602512B2/ja active Active
-
2023
- 2023-06-29 US US18/216,057 patent/US20240132535A1/en active Pending
-
2024
- 2024-01-15 AU AU2024200254A patent/AU2024200254B2/en active Active
- 2024-12-06 JP JP2024213248A patent/JP2025026574A/ja active Pending
-
2026
- 2026-05-14 AU AU2026203707A patent/AU2026203707A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519351A5 (enExample) | ||
| JP2018519329A5 (enExample) | ||
| JP2017518323A5 (enExample) | ||
| JP2019519587A5 (enExample) | ||
| RU2018104245A (ru) | Оксистеролы и способы их применения | |
| RU2018104278A (ru) | Оксистеролы и способы их применения | |
| JP2019532079A5 (enExample) | ||
| JP2015512951A5 (enExample) | ||
| RU2019115113A (ru) | Оксистеролы и способы их применения | |
| JP2017531020A5 (enExample) | ||
| JP2019529495A5 (enExample) | ||
| ME03809B (me) | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a | |
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| ATE531711T1 (de) | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate | |
| HRP20211272T1 (hr) | 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda | |
| JP2010536761A5 (enExample) | ||
| CN104254530A (zh) | 苯并噻吩化合物或其盐的二水合物及其制备方法 | |
| JP2016513663A5 (enExample) | ||
| HK1217486A1 (zh) | 作爲β-分泌酶抑制剂的全氟化环丙基稠合的1，3-恶嗪-2-胺化合物以及其使用方法 | |
| JP2015143283A5 (enExample) | ||
| NZ590951A (en) | Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders | |
| JP2010529081A5 (enExample) | ||
| EP2481478A4 (en) | CATALYST FOR CHLORINE PREPARATION BY OXIDIZING HYDROGEN CHLORIDE AND PREPARING THEREOF | |
| JP2019510794A5 (enExample) | ||
| JP2019525939A5 (enExample) |